Fighting MDR-\textit{Klebsiella pneumoniae} Infections by a Combined Host- and Pathogen-Directed Therapeutic Approach

Noemi Poerio\textsuperscript{1†}, Tommaso Olimpieri\textsuperscript{1†}, Lucia Henrici De Angelis\textsuperscript{1,2}, Federica De Santis\textsuperscript{1}, Maria Cristina Thaller\textsuperscript{1}, Marco Maria D’Andrea\textsuperscript{1} and Maurizio Fraziano\textsuperscript{1*}

\textsuperscript{1} Department of Biology, University of Rome “Tor Vergata”, Rome, Italy, \textsuperscript{2} Department of Medical Biotechnologies, University of Siena, Siena, Italy

\textit{Klebsiella pneumoniae} is an opportunistic pathogen that is very difficult to treat mainly due to its high propensity to acquire complex resistance traits. Notably, multidrug resistance (MDR)-\textit{Klebsiella pneumoniae} (KP) infections are responsible for 22\%–72\% of mortality among hospitalized and immunocompromised patients. Although treatments with new drugs or with combined antibiotic therapies have some degree of success, there is still the urgency to investigate and develop an efficient approach against MDR-KP infections. In this study, we have evaluated, in an \textit{in vitro} model of human macrophages, the efficacy of a combined treatment consisting of apoptotic body-like liposomes loaded with phosphatidylinositol 5-phosphate (ABL/PI5P) and \textit{\varphi}BO1E, a lytic phage specific for the major high-risk clone of KPC-positive MDR-KP. Results show that ABL/PI5P did not affect \textit{KKBO-1} viability, being able to reduce only the intracellular \textit{KKBO-1} bacterial load. As expected, \textit{\varphi}BO1E was effective mainly on reducing extracellular bacilli. Importantly, the combination of both treatments resulted in a simultaneous reduction of both intracellular and extracellular bacilli. Moreover, the combined treatment of \textit{KKBO-1}-infected cells reduced proinflammatory TNF-\textit{\alpha} and IL-1\textit{\beta} cytokines and increased anti-inflammatory TGF-\textit{\beta} cytokine production. Overall, our data support the therapeutic value of a combined host- and pathogen-directed therapy as a promising approach, alternative to single treatments, to simultaneously target intracellular and extracellular pathogens and improve the clinical management of patients infected with MDR pathogens such as MDR-KP.

Keywords: liposomes, phosphatidylinositol 5-phosphate, host-directed therapy, bacteriophages, phage therapy, MDR, \textit{Klebsiella pneumoniae}

INTRODUCTION

\textit{Klebsiella pneumoniae} (KP) is a major Gram-negative opportunistic bacterium included in the list of ESKAPE pathogens (\textit{Enterococcus faecium}, \textit{Staphylococcus aureus}, \textit{Klebsiella pneumoniae}, \textit{Acinetobacter baumannii}, \textit{Pseudomonas aeruginosa}, \textit{Enterobacter spp.}), known to cause opportunistic infections and characterized by a remarkable antibiotic resistance level due to accumulation of mobile antimicrobial resistance genes gained by horizontal gene transfer (1). Notably, multidrug-resistant (MDR)-KP

\textit{Open Access}

Edited by: Ian Marriott, University of North Carolina at Charlotte, United States
Reviewed by: Michal Letek, Universidad de León, Spain
*Correspondence: Maurizio Fraziano fraziano@bio.uniroma2.it
†These authors have contributed equally to this work

Specialty section: This article was submitted to Microbial Immunology, a section of the journal Frontiers in Immunology

Received: 14 December 2021
Accepted: 21 January 2022
Published: 14 February 2022

Citation: Poerio N, Olimpieri T, Henrici De Angelis L, De Santis F, Thaller MC, D’Andrea MM and Fraziano M (2022) Fighting MDR-\textit{Klebsiella pneumoniae} Infections by a Combined Host- and Pathogen-Directed Therapeutic Approach. Front. Immunol. 13:835417. doi: 10.3389/fimmu.2022.835417
infections, such as those sustained by *K. pneumoniae* carbapenemase (KPC)-producing *K. pneumoniae*, are associated with high morbidity and mortality rates, which can vary from 22% to 72% (2) and affect in particular hospitalized and immunocompromised patients. Although combined antibiotic therapies have been the most used in the last years, they have not given often satisfying results, opening the urgency to investigate and develop an efficient approach to treat MDR-KP infections (3).

We already demonstrated that apoptotic body-like (ABL) liposomes composed by a phosphatidylserine (PS) outer leaflet and an inner leaflet consisting of a bioactive lipid involved in phagocytosis process, are able to enhance macrophage intracellular bacterial killing irrespective of their drug resistance and species (4, 5). Phagocytosis is a pivotal effector mechanism of innate immunity, and second lipid messengers play a key role in phagosome formation and maturation, recruiting signal protein by means of specific lipid-binding domain, making possible the development of phagolysosome, the effective microbicidal compartment (6). In particular, the bioactive lipid phosphatidylinositol 5-phoshate (PI5P) is involved in the late stages of phagosome maturation, taking part in the vesicular traffic and in non-canonical autophagy process (6, 7). Moreover, *K. pneumoniae* is known to be able to interfere with phagocytosis process by carrying out intracellular survival strategies interfering with phagosome generation, achieving survival within vacuole compartment (*Klebsiella* containing vacuole (KCV)) and avoiding their delivery to lysosomes (8). Being an extracellular-capsulated bacterium, *K. pneumoniae* escapes macrophage phagocytosis and thus intracellular internalization. Thanks to this ability, *K. pneumoniae* is also able to form biofilms, which play an important role in interfering with the immune response, by both avoiding opsonization mechanisms and by modulating inflammatory response, contributing to the development of invasive and chronic opportunistic infections (9). On this scenario, the usage of bacteriophages for microbiocidal therapeutic purpose, also known as phage therapy, could represent an interesting and attractive option, as bacteriophages are (i) highly abundant in the environment, (ii) taking part in the vesicular trafficking, and (iii) may have a potential role in the disruption of biofilms (10, 11). On these grounds, we propose a combined host- and pathogen-directed treatment, composed of (i) ABL carrying the second lipid messenger PI5P and (ii) a phage (φBO1E) specific against KPC-positive KP (KPC-KP) clinical strains belonging to the Sequence Type (ST) 258 clade II, aimed to simultaneously target intracellular and extracellular bacilli. Before experiments, cells (2.5 × 10^5 per well) were seeded in 48-well plates and were then induced to differentiate (dTHP-1) by stimulation for 72 h with phorbol 12-myristate 13-acetate (PMA) (20 ng/ml) and used as a model of human macrophages.

**Liposome**

Apoptotic body-like liposomes (ABLs) carrying 1,2-dioleoyl-sn-glycero-3-phospho (1′-myo-inositol-5-phosphate) (PI5P, Avanti Polar Lipids) (ABL/PI5P) were produced and quantified as previously described (5).

**Bacteria**

The *K. pneumoniae* KKBO-1 clinical strain was used as a representative of the major clonal lineage of KPC-KP diffused at a worldwide scale. Single colonies of KKBO-1 were collected by streaking on Trypticase soy agar (TSA) (BD Difco™, BD Bioscience, Franklin Lakes, NJ, USA) and then suspended in 15 ml of Trypticase soy broth (TSB) (BD Difco™). Bacteria were grown in Erlenmeyer flasks at 37°C under stirring for 18 h, and their growth was monitored by measuring the optical density at the wavelength of 600 nm by Varioskan LUX Multimode Microplate Reader (Thermo Fisher Scientific, Waltham, MA, USA). Bacteria were stored at −80°C until use after suspension in Microorganism Preservation System Protect (Technical Service Consultants Ltd., Heywood, UK).

**Bacteriophage**

The φBO1E bacteriophage, a lytic phage of the *Autographiviridae* family able to selectively kill *K. pneumoniae* strains belonging to the ST258 clade II, was isolated and characterized as described by D’Andrea et al. (12).

**Evaluation of In Vitro Bacterial Growth**

To assess both extracellular and intracellular bacterial growth, dTHP-1 were plated at a concentration of 2.5 × 10^5 cells/well and were infected with KKBO-1 for 1 h at 37°C at a multiplicity of infection (MOI) of 5, in the absence of gentamycin. Cells were then washed and incubated with ABL/PI5P (ABL:cell ratio 1:1) and/or φBO1E (KKBO-1:phage ratio 2:1) for further 2 h. In order to evaluate extracellular and intracellular bacterial growth, supernatants were collected, and macrophages lysed by deoxycholate 1% (Sigma Aldrich, St. Louis, MO, USA), respectively. Finally, samples were diluted in PBS-Tween 80 and CFU quantified by plating bacilli in triplicate on TSA.

**Enzyme-Linked Immunosorbent Assay**

dTHP-1 were infected or not with KKBO-1 (MOI 5) for 1 h, and after cells were washed twice with PBS supplemented with gentamycin 500 µg/ml (Lonza), and one last time with PBS only in order to remove all extracellular bacilli. Cells were then stimulated or not for 18 h with ABL/PI5P (ABL:cell ratio 1:1) and/or φBO1E (KKBO-1: phage ratio 2:1). Thereafter, supernatants were collected and stored at −20°C until analysis. The levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and transforming growth factor-beta (TGF-β) in the supernatants of dTHP-1 were measured by human TNF-α DuoSet® ELISA Development Systems, human IL-1β DuoSet® ELISA Development Systems and human TGF-β DuoSet® ELISA Development Systems (all by R&D System, Minneapolis, MN, USA) according to the manufacturer’s instructions.

**METHOD**

**Cell Line**

Human promonocytic THP-1 leukemia cell line was supplied by the European Collection of Cell Culture, grown in RPMI-1640 containing fetal bovine serum (10%), gentamycin (5 µg/ml), L-glutamine (2 mM), nonessential amino acids (1 mM), sodium pyruvate (1 mM), and cultured in 75 cm² polystyrene flasks.
RESULTS AND DISCUSSION

Nowadays, infection diseases caused by MDR Gram-negative pathogens, such as KPC-KP, are one of the major global health concerns (3). Bacterial pathogens responsible for respiratory tract infections may cause pneumonia, which is a form of acute respiratory infection that affects the lungs and is caused by a number of infectious agents. In particular, opportunistic pathogens have been identified as causative agents of different respiratory tract infections and in the last years there was an increased incidence of MDR strains (5). In this context, infections due to MDR-KP are associated with a high mortality among hospitalized and immunocompromised patients, and the optimal antibiotic combination regimen to control and resolve such infections has not been established yet (3). On these grounds, the development of different strategies that may support standard pathogen-directed therapies (PDTs), such as antibiotics, for the management of MDR-KP infections is considered urgent. It was already demonstrated that the contextual administration of host-directed therapies (HDTs), as immunomodulators, and antibiotics proved to be highly effective against MDR pathogens such as Mycobacterium tuberculosis and P. aeruginosa (13). Based on this evidence, we decided to combine an alternative PDT consisting in specific bacteriophages against KKBO-1 KPC-KP clinical strain (qBO1E) (12) with a novel HDT based on ABL/Pi5P for the treatment of MDR-KP infections. In this context ABL/Pi5P was chosen given its ability to enhance phagocytosis which represents one of the main innate immune response mechanisms that can be enhanced via HDT (14, 15).

We have recently demonstrated that ABL loaded with Pi5P is able to enhance antimicrobial response in bronchoalveolar lavage (BAL) cells isolated from patients with pneumonia due to MDR pathogens, including MDR-KP (5). Furthermore, we reported that in an in vivo model of Mycobacterium abscessus chronic infection, the combined treatment with ABL/Pi5P and amikacin promotes a significant additional reduction of both pulmonary mycobacterial burden and inflammatory response in comparison with single treatments, with no signs of kidney and liver toxicity (16).

Antibiotic administration represents the worldwide most common PDT used to treat infections so far, but, recently, alternative PDTs have been proposed, with phage therapy representing a very promising candidate to be used as supplement or even replacement of antibiotic treatments (17). This is particularly true considering that the pandemic dissemination of KPC-KP is mainly sustained by a single clonal lineage, i.e., strains belonging to the clade II of the clonal group 258. In this scenario, the use of bacteriophages is a promising approach, given the already existing evidence of their in vivo efficacy by using intranasal administration against a wide range of pathogens, comprising MDR-KP (18). Coherently with this evidence, we show that the treatment with ABL/Pi5P is able to enhance the intracellular clearance (Figure 1B) of the KKBO-1 KPC-KP clinical strain, with no effect on bacilli viability (Figure 1A). Moreover, here, we demonstrated that qBO1E is able to kill extracellular KKBO-1 (Figure 1A), even though we noticed a reduction in intracellular microbial presence after phage treatment (Figure 1B). This may be due to the already described ability of some bacteriophages to penetrate inside macrophages or to the fortuitous engulfment of phage-infected bacteria by macrophages (19).

More importantly, we also demonstrated that when combined, ABL/Pi5P and qBO1E succeed in reducing extracellular bacterial burden and in enhancing antimicrobial activity of macrophages at once, producing an additive effect statistically more significant than the two single treatments (Figure 1B), without having any cytotoxic effect (Supplementary Material S1). Lastly, inflammation plays a crucial role as first-line defense mechanism in a context of infection, and a successful cytokine profile modulation is critical to design an effective HDT strategy. The net effect of an inflammatory response is determined by the balance between pro- and anti-inflammatory cytokines secreted by a broad range of cells, including macrophages, and is needed in order to avoid immunopathology.
The ABL/PI5P ability in modulating cytokine production in a context of MDR pathogen infection has already been described (21), while immunogenicity of phages generally does not represent a safety risk for patients (19). Coherently with these findings, we demonstrated that the combined treatment is able to downregulate the proinflammatory TNF-α (Figure 2A) and IL-1β (Figure 2B) cytokine production, while at same time upregulating anti-inflammatory cytokine TGF-β (Figure 2C) levels, making it a suitable approach for chronic KPC-KP infection treatment. Additionally, φBO1E alone does not induce changes in uninfected dTHP-1 cell cytokine production profiles, confirming its low immunogenicity.

The results reported herein show that this strategy may improve the current therapeutic regimens to help in preserving the few effective
drugs (e.g., colistin and newer beta-lactam/beta-lactamase inhibitor combinations) still available against such pathogens (22). The lack of in vivo results and the use of a single bacteriophage strain represent an important limitation to the prompt clinical applicability of our therapeutic strategy. Indeed, preclinical studies are mandatory to solve several safety and efficacy concerns such as (i) phage effect on body tissues or nontarget microbiota, (ii) host immune system phage clearance and degradation, and (iii) the emergence of phage-resistant K. pneumoniae strains (19, 23, 24). In this context, our study was designed to be the proof of concept aimed at providing the basis for the necessary improvements required for subsequent preclinical studies, such as the use of PDTs based on phage cocktails or phage/antibiotic combinations. However, it has to be mentioned that ifBoIE targets the capsular polysaccharide of KP-KP of the clade II of ST258 and in vivo model of KKBO-1-infected Galleria mellonella, during phage treatment, capsular-deficient K. pneumoniae clones can be selected and are characterized by a lower pathogenicity. This evidence suggests that in the context of the interplay among phage, pathogen, and host, the emergence of phage-resistant bacteria may, in this specific case, also be beneficial for the host (25).

Overall, our data support the potential of the combined host and phage therapy as an attractive complement or alternative tool to antibiotic treatment against MDR infections and shed light on an innovative combined approach, targeting at the same time intracellular and extracellular pathogens, improving the clinical management of patients, and limiting the diffusion, the increase, and the spread of MDR pathogen strains.

REFERENCES

1. Pendleton JN, Gorman SP, Gilmore BF. Clinical Relevance of the ESKAPE Pathogens. Expert Rev Anti Infect Ther (2013) 11:297–308. doi: 10.1586/ ERI.13.12
2. Tumbarello M, Treccarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, et al. Infections Caused by KPC-Producing Klebsiella Pneumoniae: Differences in Therapy and Mortality in a Multicentre Study. J Antimicrob Chemother (2015) 70:2313–43. doi: 10.1093/JAC/DKV086
3. Bassetti M, Riggi E, Carmelutti A, Graziano E, Russo A. Multidrug-Resistant Klebsiella Pneumoniae: Challenges for Treatment, Prevention and Infection Control. Expert Rev Anti Infect Ther (2018) 16:749–61. doi: 10.1080/ 14787210.2018.1522249
4. Greco E, Quintilliani G, Santucci MB, Serafin A, Ciccaglione AR, Marcantonio C, et al. Janus-Faced Liposomes Enhance Antimicrobial Innate Immune Response in Mycobacterium Tuberculosis Infection. Proc Natl Acad Sci USA (2012) 109:E360–8. doi: 10.1073/PNAS.120048109
5. Poerio N, Bugli F, Taus F, Santucci MB, Rodolfo C, Cecconi F, et al. Liposomes Loaded With Bioactive Lipids Enhance Antibacterial Innate Immunity Irrespective of Drug Resistance. Sci Rep (2017) 7:45120. doi: 10.1038/SREP45120
6. Nisini R, Poerio N, Mariotti S, De Santis F, Frazierio M. The Multirole of Therapeutic Liposomes in Therapy and Prevention of Infectious Diseases. Front Immunol (2018) 9:155. doi: 10.3389/FIMMU.2018.00155
7. Vicenanza M, Korolchuk VI, Ashkenazi A, Puri C, Menzies FM, Clarke JH, et al. PI(3)P Regulates Autophagosome Biogenesis. Mol Cell (2015) 57:219– 34. doi: 10.1016/J.MOLCEL.2014.12.007
8. Cano V, March C, Issua JL, Aiguilo N, Llobet E, Moranta D, et al. Klebsiella Pneumoniae Survives Within Macrophages by Avoiding Delivery to Lysosomes. Cell Microbiol (2015) 17:1537–60. doi: 10.1111/CML.12466
9. Piperaki ET, Syriogiannopoulos GA, Tsouveleki LS, Daikos GL. Klebsiella Pneumoniae: Virulence, Biofilm and Antimicrobial Resistance. Pediatr Infect Dis J (2017) 36:1002–5. doi: 10.1097/INF.0000000000001675
10. Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, et al. Formulation, Stabilisation and Encapsulation of Bacteriophage for Phage Therapy. Adv Colloid Interface Sci (2017) 249:100–33. doi: 10.1016/ j.cis.2017.05.014
11. Sutherland IW, Hughes KA, Skillman LC, Tait K. The Interaction of Phage and Biofilms. FEMS Microbiol Lett (2004) 232:1–6. doi: 10.1016/S0378-1097 (04)00041-2
12. D’Andrea MM, Marmo P, Henrici De Angelis L, Palmieri M, Ciaci N, Di Lallo G, et al. φBo1e, A Newly Discovered Lytic Bacteriophage Targeting Carbapenemase-Producing Klebsiella Pneumoniae of the Pandemic Clonal Group 258 Clade II Lineage. Sci Rep (2017) 7:2614. doi: 10.1038/S41598-017- 02788-9
13. Maeruer M, Rao M, Zumla A. Host-Directed Therapies for Antimicrobial Resistant Respiratory Tract Infections. Curr Opin Pulm Med (2016) 22 (3):203–11. doi: 10.1097/MCP.0000000000000271
14. Kaufmann SHE, Dorhoi A, Hotchkiss RS, Bartenschlager R. Host-Directed Therapies for Bacterial and Viral Infections. Nat Rev Drug Discovery (2018) 17 (1):35–56. doi: 10.1038/nrd.2017.162
15. Zumla A, Rao M, Wallis RF, Kaufmann SH, Rustomjee R, Mwaba P, et al. Host-Directed Therapies Network Consortium. Host-Directed Therapies for Infectious Diseases: Current Status, Recent Progress, and Future Prospects. Lancet Infect Dis (2016) 16(4):e47–63. doi: 10.1016/S1473-3099(16)00078-5
16. Poerio N, Riva C, Olimpieri T, Rossi M, Lorè NI, De Santis F, et al. Combined Host- and Pathogen-Directed Therapy for the Control of Mycobacterium Aecessus Infection. Microbiol Spectr (2022). Published online ahead of print. doi: 10.1128/spectrum.02546-21
17. Lin DM, Koskella B, Lin HC. Phage Therapy: An Alternative to Antibiotics in the Age of Multi-Drug Resistance. World J Gastrointest Pharmacol Ther (2017) 8(3):162–73. doi: 10.4292/wjgpt.v8.i3.162
18. Anand T, Virmani N, Kumar S, Mohanty AK, Pavulraj S, Bera RC, et al. Phage Therapy for Treatment of Virulent Klebsiella Pneumoniae Infection in a Mouse Model. J Glob Antimicrob Resist (2020) 21:34–41. doi: 10.1016/ j.jgar.2019.09.018

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

MCT, MMDA, and MF contributed to the conception and design of the study. NP, TO, LHDA, and FDS, contributed to data acquisition. NP, TO, MMDA, and MF participated in data analysis and manuscript writing. All authors read and approved the final manuscript.

FUNDING

The research was supported by the Italian Cystic Fibrosis Research Foundation, FFC #21/2019.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.835417/full?supplementary-material
19. Krut O, Bekeredjian-Ding I. Contribution of the Immune Response to Phage Therapy. *J Immunol (Baltimore Md: 1950)* (2018) 200:3037–44. doi: 10.4049/JIMMUNOL.1701745

20. Kany S, Vollrath JT, Relja B. Cytokines in Inflammatory Disease. *Int J Mol Sci* (2019) 20:6008. doi: 10.3390/IJMS20236008

21. Poerio N, De Santis F, Rossi A, Ranucci S, De Fino I, Henriquez A, et al. Liposomes Loaded With Phosphatidylinositol 5-Phosphate Improve the Antimicrobial Response to *Pseudomonas Aeruginosa* in Impaired Macrophages From Cystic Fibrosis Patients and Limit Airway Inflammatory Response. *Front Immunol* (2020) 11:532225. doi: 10.3389/FIMMU.2020.532225

22. Loho T, Dharmayanti A. Colistin: An Antibiotic and its Role in Multiresistant Gram-Negative Infections. *Acta Med Indones* (2015) 47(2):157–68.

23. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage Treatment of Human Infections. *Bacteriophage* (2011) 1(2):66–85. doi: 10.4161/bact.1.2.15845

24. Hodyra-Stefaniak K, Miernikiewicz P, Drapala J, Drab M, Jonczyk-Matysiak E, Lecion D, et al. Mammalian Host-Versus-Phage Immune Response Determines Phage Fate *In Vivo*. *Sci Rep* (2015) 5:14802. doi: 10.1038/srep14802

25. Henrici De Angelis L, Poerio N, Di Pilato V, De Santis F, Antonelli A, Thaller MC, et al. Phage Resistance is Associated With Decreased Virulence in KPC-Producing *Klebsiella Pneumoniae* of the Clonal Group 258 Clade II Lineage. *Microorganisms* (2021) 9:762. doi: 10.3390/microorganisms9040762

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Poerio, Olimpieri, Henrici De Angelis, De Santis, Thaller, D’Andrea and Fraziano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.